226 related articles for article (PubMed ID: 11178347)
1. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
Yassin HM; Dever LL
Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
[TBL] [Abstract][Full Text] [Related]
2. Microbiological profile of telithromycin, the first ketolide antimicrobial.
Felmingham D
Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558
[TBL] [Abstract][Full Text] [Related]
3. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
Lorenz J
Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
[TBL] [Abstract][Full Text] [Related]
4. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.
Lonks JR; Goldmann DA
Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365
[TBL] [Abstract][Full Text] [Related]
5. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
Low DE; Brown S; Felmingham D
Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
[TBL] [Abstract][Full Text] [Related]
6. Telithromycin: the first ketolide for the treatment of respiratory infections.
Kasbekar N; Acharya PS
Am J Health Syst Pharm; 2005 May; 62(9):905-16. PubMed ID: 15851496
[TBL] [Abstract][Full Text] [Related]
7. Telithromycin: an oral ketolide for respiratory infections.
Bearden DT; Neuhauser MM; Garey KW
Pharmacotherapy; 2001 Oct; 21(10):1204-22. PubMed ID: 11601667
[TBL] [Abstract][Full Text] [Related]
8. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
9. Telithromycin.
Balfour JA; Figgitt DP
Drugs; 2001; 61(6):815-29; discussion 830-1. PubMed ID: 11398913
[TBL] [Abstract][Full Text] [Related]
10. The ketolides: a critical review.
Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ
Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
12. Telithromycin: the first of the ketolides.
Shain CS; Amsden GW
Ann Pharmacother; 2002 Mar; 36(3):452-64. PubMed ID: 11895060
[TBL] [Abstract][Full Text] [Related]
13. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.
Hammerschlag MR; Sharma R
Expert Opin Investig Drugs; 2008 Mar; 17(3):387-400. PubMed ID: 18321237
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
Kohno S; Hoban D;
J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
[TBL] [Abstract][Full Text] [Related]
15. [Telithromycin, a once-a-day ketolide in the treatment of community acquired pneumonia].
Carbon C
Presse Med; 2000 Dec; 29(37):2042-3. PubMed ID: 11155730
[TBL] [Abstract][Full Text] [Related]
16. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of new antibacterial therapies in at-risk populations.
Lorenz J
J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
Walsh F; Carnegy F; Willcock J; Amyes S
J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
[TBL] [Abstract][Full Text] [Related]
19. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
Felmingham D; Zhanel G; Hoban D
J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
Farrell DJ; Sader HS; Castanheira M; Biedenbach DJ; Rhomberg PR; Jones RN
Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
